Akums Drugs & Pharma Stock Screener | Share Price & Fundamental Analysis

AKUMS Pharmaceuticals
Screen Akums Drugs & Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹444.80
▼ -2.55 (-0.57%)
2026-01-06 00:00:00
Share Price BSE
₹444.20
▼ -3.25 (-0.73%)
2026-01-06 00:00:00
Market Cap ₹7,018.20 Cr.
P/B Ratio 2.27
EPS (TTM) ₹22.60
Dividend Yield -
Debt to Equity 0.17
52W High ₹632.70
52W Low ₹414.05
Operating Margin 9.00%
Profit Margin 4.10%
Revenue (TTM) ₹1,050.00
EBITDA ₹127.00
Net Income ₹43.00
Total Assets ₹4,113.00
Total Equity ₹3,064.00

Akums Drugs & Pharma Share Price History - Stock Screener Chart

Screen AKUMS historical share price movements with interactive charts. Analyze price trends and patterns.

Akums Drugs & Pharma Company Profile - Fundamental Screener

Screen Akums Drugs & Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AKUMS shares.
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE09XN01023

Akums Drugs & Pharma Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen AKUMS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020
Assets
Total Assets 4,113 3,516 3,267 3,069 2,192 2,078
Current Assets 2,275 1,941 1,879 1,864 1,157 1,250
Fixed Assets 1,397 1,191 1,097 1,021 834 645
Liabilities
Total Liabilities 4,113 3,516 3,267 3,069 2,192 2,078
Current Liabilities 156 1,585 1,278 1,172 725 627
Non-Current Liabilities 0 0 0 0 0 0
Shareholders' Equity
Total Equity 3,064 721 723 625 887 721
Share Capital 31 29 29 14 1 1
Reserves & Surplus 3,016 681 689 608 884 721
Screen AKUMS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun
Revenue 1,050 1,051 1,081 1,030 1,050 1,026 955 1,093 1,188 978
Expenses 923 895 962 889 912 891 941 989 1,057 1,095
EBITDA 127 156 120 141 138 135 14 103 131 -117
Operating Profit % 9.00% 13.00% 9.00% 12.00% 12.00% 13.00% 0.00% 9.00% 11.00% -13.00%
Depreciation 38 37 40 45 35 34 34 32 30 30
Interest 23 23 5 5 12 13 12 12 14 12
Profit Before Tax 66 96 75 91 92 88 -33 59 87 -159
Tax 23 31 -75 25 25 26 7 -136 54 29
Net Profit 43 65 150 66 67 61 -40 195 33 -187
EPS 2.66 4.15 9.64 4.26 4.37 4.21 -2.89 13.21 2.22 -13.16

Akums Drugs & Pharma Cash Flow Screener - Liquidity Fundamentals

Screen AKUMS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2016-March 2015-March
Operating Activities 465 498 177 32 135 28 89 72
Investing Activities -548 -331 -305 -235 -109 -190 -123 -150
Financing Activities 73 -108 125 236 -95 233 37 66
Net Cash Flow -10 59 -4 33 -70 71 4 -11
Screen AKUMS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Aug 2024-Feb
Promoter Holding 75.26% 75.26% 75.26% 75.26% 75.26% 75.26% 84.91%
FII Holding 2.28% 4.24% 5.77% 6.36% 7.34% 5.32% 0.00%
DII Holding 9.28% 8.85% 7.40% 7.00% 7.52% 7.60% 0.00%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 5.01% 3.60% 3.41% 3.33% 2.11% 4.43% 0.00%
Other Holding 8.18% 8.05% 8.16% 8.05% 7.77% 7.38% 15.09%
Shareholder Count 75,365 69,424 69,366 68,410 57,531 138,205 8

Akums Drugs & Pharma Dividend Screener - Share Yield Analysis

Screen AKUMS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
No dividends declared by Akums Drugs & Pharma.

Akums Drugs & Pharma Index Membership - Market Screener Classification

Screen AKUMS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.

Akums Drugs & Pharma Market Events Screener - Corporate Actions

Screen AKUMS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
2025-11-13 2025-11-13 Quarterly Result Announcement NA -0.29%
2025-08-08 2025-08-08 Quarterly Result Announcement NA -4.50%
2025-07-18 2025-07-18 Annual General Meeting NA -1.09%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 3.58%
2025-02-06 2025-02-06 Quarterly Result Announcement NA 0.66%
2024-11-09 2024-11-09 Quarterly Result Announcement NA -5.76%

Akums Drugs & Pharma Competitors Screener - Peer Comparison

Screen AKUMS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 412,950 39.35 54,729 9.71% 10,980 39.47
Divis Laboratories 168,413 68.31 9,712 18.67% 2,191 44.14
Torrent Pharmaceuticals 130,247 60.76 11,539 6.99% 1,911 62.90
Cipla 121,238 22.46 28,410 7.12% 5,291 46.90
Dr Reddys Laboratories 104,613 18.49 33,741 16.73% 5,725 43.77
Lupin 96,056 22.19 22,910 13.74% 3,306 55.44
Zydus Life Science 92,075 18.30 23,511 18.55% 4,615 44.07
Mankind Pharma 89,356 51.11 12,744 20.90% 2,007 44.20
Aurobindo Pharma 69,290 20.05 32,346 9.43% 3,484 49.09
Alkem Laboratories 65,324 27.31 13,458 3.70% 2,216 38.49

Akums Drugs & Pharma Company Announcements - News Screener

Screen AKUMS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-01-03 Resignation Of Senior Management Personnel View
2026-01-03 Closure of Trading Window View
2025-12-29 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 View
2025-12-29 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 View
2025-12-16 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update View
2025-12-15 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 View
2025-12-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-17 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2025-11-14 Announcement under Regulation 30 (LODR)-Monitoring Agency Report View
2025-11-14 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-14 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2025-11-14 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-11-13 Update View
2025-11-13 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-11-13 Announcement under Regulation 30 (LODR)-Investor Presentation View
2025-11-13 Outcome Of Board Meeting View
2025-11-13 Board Meeting Outcome for Outcome Of Board Meeting View
2025-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-08 Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Half Year Ended On 30Th September 2025 View